384 related articles for article (PubMed ID: 26460956)
41. Reversibility of Left Ventricle Longitudinal Strain Alterations Induced by Adjuvant Therapy in Early Breast Cancer Patients.
Mele D; Malagutti P; Indelli M; Ferrari L; Casadei F; Da Ros L; Pollina A; Fiorencis A; Frassoldati A; Ferrari R
Ultrasound Med Biol; 2016 Jan; 42(1):125-32. PubMed ID: 26603736
[TBL] [Abstract][Full Text] [Related]
42. Left atrial volume in patients with HER2-positive breast cancer: One step further to predict trastuzumab-related cardiotoxicity.
Bergamini C; Dolci G; Rossi A; Torelli F; Ghiselli L; Trevisani L; Vinco G; Truong S; La Russa F; Golia G; Molino A; Benfari G; Ribichini FL
Clin Cardiol; 2018 Mar; 41(3):349-353. PubMed ID: 29569424
[TBL] [Abstract][Full Text] [Related]
43. New Cardiac Abnormalities After Radiotherapy in Breast Cancer Patients Treated With Trastuzumab.
Nack E; Koffer PP; Blumberg CS; Leonard KL; Huber KE; Fenton MA; Dizon DS; Wazer DE; Hepel JT
Clin Breast Cancer; 2020 Jun; 20(3):246-252. PubMed ID: 32067901
[TBL] [Abstract][Full Text] [Related]
44. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.
Fallah-Rad N; Walker JR; Wassef A; Lytwyn M; Bohonis S; Fang T; Tian G; Kirkpatrick ID; Singal PK; Krahn M; Grenier D; Jassal DS
J Am Coll Cardiol; 2011 May; 57(22):2263-70. PubMed ID: 21616287
[TBL] [Abstract][Full Text] [Related]
45. Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer.
Yu AF; Yadav NU; Lung BY; Eaton AA; Thaler HT; Hudis CA; Dang CT; Steingart RM
Breast Cancer Res Treat; 2015 Jan; 149(2):489-95. PubMed ID: 25552363
[TBL] [Abstract][Full Text] [Related]
46. Acute Cardiotoxicity With Concurrent Trastuzumab and Hypofractionated Radiation Therapy in Breast Cancer Patients.
Sayan M; Abou Yehia Z; Gupta A; Toppmeyer D; Ohri N; Haffty BG
Front Oncol; 2019; 9():970. PubMed ID: 31632906
[No Abstract] [Full Text] [Related]
47. Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab.
Davis CC; Zelnak A; Eley JW; Goldstein DA; Switchenko JM; McKibbin T
Ann Pharmacother; 2016 Sep; 50(9):712-7. PubMed ID: 27307412
[TBL] [Abstract][Full Text] [Related]
48. Cardiac magnetic resonance imaging-based myocardial strain study for evaluation of cardiotoxicity in breast cancer patients treated with trastuzumab: A pilot study to evaluate the feasibility of the method.
Nakano S; Takahashi M; Kimura F; Senoo T; Saeki T; Ueda S; Tanno J; Senbonmatsu T; Kasai T; Nishimura S
Cardiol J; 2016; 23(3):270-80. PubMed ID: 27173679
[TBL] [Abstract][Full Text] [Related]
49. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
Telli ML; Hunt SA; Carlson RW; Guardino AE
J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
[TBL] [Abstract][Full Text] [Related]
50. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
Vulsteke C; Pfeil AM; Maggen C; Schwenkglenks M; Pettengell R; Szucs TD; Lambrechts D; Dieudonné AS; Hatse S; Neven P; Paridaens R; Wildiers H
Breast Cancer Res Treat; 2015 Jul; 152(1):67-76. PubMed ID: 26017071
[TBL] [Abstract][Full Text] [Related]
51. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
Guarneri V; Lenihan DJ; Valero V; Durand JB; Broglio K; Hess KR; Michaud LB; Gonzalez-Angulo AM; Hortobagyi GN; Esteva FJ
J Clin Oncol; 2006 Sep; 24(25):4107-15. PubMed ID: 16908934
[TBL] [Abstract][Full Text] [Related]
52. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.
Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M
Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of Cardiotoxicity in HER-2-Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab.
Bachir B; Anouti S; Abi Jaoude J; Kayali M; Tfayli A; de Azambuja E; Poortmans P; Zeidan YH
Int J Radiat Oncol Biol Phys; 2022 May; 113(1):135-142. PubMed ID: 34986381
[TBL] [Abstract][Full Text] [Related]
54. Brain natriuretic peptide as a cardiac marker of transient radiotherapy-related damage in left-sided breast cancer patients: A prospective study.
Palumbo I; Palumbo B; Fravolini ML; Marcantonini M; Perrucci E; Latini ME; Falcinelli L; Sabalich I; Tranfaglia C; Schillaci G; Mannarino E; Aristei C
Breast; 2016 Feb; 25():45-50. PubMed ID: 26547836
[TBL] [Abstract][Full Text] [Related]
55. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment.
Harris EE; Correa C; Hwang WT; Liao J; Litt HI; Ferrari VA; Solin LJ
J Clin Oncol; 2006 Sep; 24(25):4100-6. PubMed ID: 16908933
[TBL] [Abstract][Full Text] [Related]
56. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
[TBL] [Abstract][Full Text] [Related]
57. Retrospective analysis of cardiac tolerability of concurrent administration of trastuzumab and anthracycline-based regimen for breast cancer, to address one-year-term issues in LVEF.
Watanabe N; Otsuka S; Sasaki Y; Yuasa T; Shimada K
Breast Dis; 2015; 35(4):253-61. PubMed ID: 26518668
[TBL] [Abstract][Full Text] [Related]
58. Trastuzumab-induced cardiomyopathy: incidence and associated risk factors in an inner-city population.
Baron KB; Brown JR; Heiss BL; Marshall J; Tait N; Tkaczuk KH; Gottlieb SS
J Card Fail; 2014 Aug; 20(8):555-9. PubMed ID: 24905295
[TBL] [Abstract][Full Text] [Related]
59. Troponin T-release associates with cardiac radiation doses during adjuvant left-sided breast cancer radiotherapy.
Skyttä T; Tuohinen S; Boman E; Virtanen V; Raatikainen P; Kellokumpu-Lehtinen PL
Radiat Oncol; 2015 Jul; 10():141. PubMed ID: 26159409
[TBL] [Abstract][Full Text] [Related]
60. Factors for time to trastuzumab-induced cardiotoxicity in breast cancer patients.
Lee MH; Yee J; Kim YJ; Moon JY; Kim JH; Rhie SJ; Gwak HS
Med Oncol; 2017 Nov; 34(12):199. PubMed ID: 29164397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
